Apogee Therapeutics, Inc. Liquidation Value
APGE
Other
Cash & Equivalents
$131.55M
As of 2025-12-31
Current Price: N/A
Key Metrics
Cash Liquidation Value
Cash minus Total Obligations
Cash: $131.55M
Total Obligations: -$36.76M
$94.79M
Per share: $1.39
Period: 2025-12-31
Liquid Liquidation Value
Cash + AR minus Total Obligations
Cash: $131.55M
AR: $0
Total Obligations: -$36.76M
$94.79M
Per share: $1.39
Period: 2025-12-31
Operating Liquidation Value
Cash + AR + Inventory minus Total Obligations
Cash: $131.55M
AR: $0
Inventory: $0
Total Obligations: -$36.76M
$94.79M
Per share: $1.39
Period: 2025-12-31
Build your own liquidation scenario
Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.
Liquidation Ladder
| Metric | Total | Per Share |
|---|---|---|
| Cash Liquidation Value | $94.79M | $1.39 |
| Liquid Liquidation Value | $94.79M | $1.39 |
| Operating Liquidation Value | $94.79M | $1.39 |
Key Components (as of 2025-12-31)
| Cash & Equivalents | $131.55M |
| Accounts Receivable | N/A |
| Inventory | N/A |
| Current Liabilities | $27.91M |
| Long-term Debt | N/A |
| Op. Lease Liability | $8.85M |
| Finance Lease | N/A |
| Shares Outstanding | 68.4M |
Explore all 136 XBRL tags and build your own scenario → Open Calculator
Historical
| Period | Cash | AR | Inventory | AP | Curr Liab | LT Debt | Op Lease | Fin Lease |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $131.55M | N/A | N/A | $1.22M | $27.91M | N/A | $8.85M | N/A |
| 2025-09-30 | $107.91M | N/A | N/A | $376,000 | $34.05M | N/A | $9.85M | N/A |
| 2025-06-30 | $124.19M | N/A | N/A | $5.68M | $31.55M | N/A | $10.85M | N/A |
| 2025-03-31 | $106.92M | N/A | N/A | $2.44M | $32.96M | N/A | $11.82M | N/A |
| 2024-12-31 | $141.79M | N/A | N/A | $1.07M | $28.56M | N/A | $11.83M | N/A |
| 2024-09-30 | $118.78M | N/A | N/A | $2.22M | $32.61M | N/A | $12.14M | N/A |
| 2024-06-30 | $307.30M | N/A | N/A | $5.53M | $24.62M | N/A | $4.08M | N/A |
| 2024-03-31 | $485.46M | N/A | N/A | $4.30M | $21.55M | N/A | $1.77M | N/A |
▼ Community Notes